{"gene":"EPHB4","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1994,"finding":"EphB4 (originally cloned as HTK) is a transmembrane receptor tyrosine kinase of the EPH subfamily that autophosphorylates on tyrosine and exhibits intrinsic kinase activity in vitro; antibodies against its extracellular domain act as agonists inducing tyrosine phosphorylation in transfected cells.","method":"In vitro kinase assay with purified in vitro translated protein; immunoprecipitation; agonistic antibody stimulation in transfected NIH3T3 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — original cloning paper with in vitro kinase reconstitution and autophosphorylation assay","pmids":["8188704"],"is_preprint":false},{"year":1999,"finding":"EphB4 is selectively expressed on venous (not arterial) endothelial cells in embryos, and targeted loss-of-function of EphB4 phenocopies the ephrin-B2 knockout, demonstrating that ephrin-B2/EphB4 interactions are intrinsically required in vascular endothelial cells for angiogenesis via bidirectional signaling.","method":"Targeted gene knockout in mice; comparative phenotypic analysis with ephrin-B2 null mice; immunohistochemistry for expression pattern","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal genetic loss-of-function with clear phenotypic readout, replicated across two mutant lines","pmids":["10518221"],"is_preprint":false},{"year":2003,"finding":"EphB4 forward signaling (via its kinase domain activated by ephrin-B2) inhibits endothelial cell adhesion, whereas EphB4-mediated reverse signaling through ephrin-B2 does not inhibit adhesion; cell migration is inhibited on immobilized ephrin-B2-Fc but not on EphB4-Fc, demonstrating distinct functional roles of forward vs. reverse signaling in arterial-venous endothelial cell interactions.","method":"Cell adhesion and migration assays using sorted primary endothelial cells and cell lines treated with immobilized Fc-fusion proteins","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional assays distinguishing forward vs. reverse signaling, single lab","pmids":["12588758"],"is_preprint":false},{"year":2004,"finding":"EphB4 on tumor cells promotes angiogenesis and tumor growth by interacting with ephrin-B2 on vascular endothelial cells; the extracellular domain of EphB4 attracts endothelial cells and stimulates endothelial cell invasion, survival, and proliferation in vitro, and EphB4 lacking the kinase domain (dominant negative) still promotes blood vessel enlargement in vivo via reverse ephrin-B2 signaling.","method":"Mouse xenograft model; in vitro endothelial cell migration/invasion/survival assays; EGFP-tagged kinase-dead EphB4 constructs","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — kinase-dead construct dissects forward vs. reverse signaling, in vitro and in vivo evidence","pmids":["15067119"],"is_preprint":false},{"year":2004,"finding":"EphB4 signaling mediates ephrinB2-induced inhibition of cell migration; EphB4 kinase activity is essential for this effect, as demonstrated by relief of migration inhibition upon treatment with the Src-family kinase inhibitor PP2 (which also inhibits EphB4 kinase).","method":"Cell migration assay in a system solely dependent on ephrinB2-EphB4 signaling; pharmacological kinase inhibition with PP2 and PD153035","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — functional migration assay with kinase inhibition demonstrating requirement for catalytic activity, single lab","pmids":["14672701"],"is_preprint":false},{"year":2004,"finding":"Upon EphB4 activation by ephrinB2, syndecan-1 and syntenin are upregulated in EphB4-positive endothelial cells in a dose- and time-dependent manner; upregulated syndecan-1 can compete with FGFR for bFGF, suppressing angiogenesis in vitro, but heparanase (present in inflamed tissue) cleaves syndecan-1 and converts the inhibitory effect to an activating one in vivo.","method":"cDNA microarray followed by RT-PCR; in vitro angiogenesis assay; preclustered ephrinB2 stimulation of endothelial cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (microarray, RT-PCR, functional assay) identifying downstream targets, single lab","pmids":["15126321"],"is_preprint":false},{"year":2006,"finding":"Crystal structure of the EphB4 ligand-binding domain in complex with an antagonist peptide at 1.65 Å resolution reveals the peptide occupies the hydrophobic cleft corresponding to the ephrin-B2 G-H loop binding site; specific residues in this cleft determine EphB4 ligand specificity, and isothermal titration calorimetry identified peptide residues critical for receptor binding.","method":"X-ray crystallography at 1.65 Å; isothermal titration calorimetry with truncated peptide variants","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with thermodynamic validation, defines molecular determinants of ligand specificity","pmids":["16472751"],"is_preprint":false},{"year":2006,"finding":"Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis: reverse signaling through ephrinB2 (expressed by osteoclast precursors) suppresses osteoclast differentiation by inhibiting the c-Fos–NFATc1 cascade, while forward signaling through EphB4 (expressed by osteoblasts) enhances osteoblast differentiation; transgenic overexpression of EphB4 in osteoblasts increases bone mass.","method":"Gain- and loss-of-function mouse experiments; transgenic EphB4 overexpression; analysis of c-Fos and NFATc1 signaling; bone histomorphometry","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — bidirectional pathway dissected with multiple genetic models and defined molecular cascades, highly cited foundational study","pmids":["16890539"],"is_preprint":false},{"year":2006,"finding":"EphB4 forward signaling promotes melanoma cell migration via activation of RhoA and consequent actin cytoskeleton reorganization; EphB4 kinase activity is required, as kinase-dead EphB4 inhibits migration and actin organization, and dominant negative RhoA blocks the pro-migratory effect of active EphB4.","method":"Overexpression/kinase-dead EphB4 constructs; dominant negative RhoA; cell migration assays; RhoA activity pull-down assay; actin cytoskeleton imaging","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple constructs and orthogonal assays establishing kinase-dependent RhoA-mediated mechanism","pmids":["16950769"],"is_preprint":false},{"year":2006,"finding":"EphB4 promotes breast cancer cell survival and acts as a survival factor; phosphorylation by its ligand EphrinB2 activates the PI3K/AKT pathway; EphB4 knockdown by siRNA induces apoptosis via caspase activation and sensitizes cells to TRAIL.","method":"siRNA knockdown; antisense oligonucleotides; cell viability and apoptosis assays; caspase activation assay; mouse xenograft model","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined pathway (AKT) and phenotypic readout, single lab","pmids":["16816380"],"is_preprint":false},{"year":2008,"finding":"EphrinB2/EphB4 signaling functions to sort arterial and venous endothelial cells into their respective vessels during angiogenesis; loss of ephrin B2 or EphB4 leads to mislocalization of venous-identity cells into the aorta, whereas Notch controls the relative size of arteries and veins by affecting arterial-to-venous endothelial cell proportions.","method":"Mouse genetic loss-of-function models; endothelial cell lineage tracing and localization analysis; comparison with Notch gain/loss-of-function","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with mechanistic distinction from Notch pathway, multiple mutant alleles","pmids":["18952909"],"is_preprint":false},{"year":2009,"finding":"EphB4 inhibits integrin-mediated cell-substrate adhesion, spreading, and migration in cancer cells in an ephrin-ligand-independent manner; this requires EphB4 kinase activity, and is associated with reduced β1-integrin protein levels. Mutations impairing ephrin binding do not affect this ligand-independent adhesion inhibition, demonstrating a constitutive, kinase-dependent function.","method":"siRNA knockdown; transient overexpression; single amino acid mutations impairing ephrin binding; cell adhesion/spreading/migration assays; western blotting for β1-integrin","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (siRNA, overexpression, binding-deficient mutants) establishing ligand-independent, kinase-dependent mechanism","pmids":["19552627"],"is_preprint":false},{"year":2009,"finding":"EphB4 has tumor suppressor activities in intestinal tumorigenesis; inactivation of a single EphB4 allele in ApcMin mice results in increased proliferation, larger and more numerous intestinal tumors, and a 25% shorter lifespan; loss of EPHB4 in colon cancer cells increases invasive potential through extracellular matrix.","method":"Genetic mouse model (ApcMin × EphB4 heterozygous knockout); in vitro invasion assay; gene expression profiling; xenograft model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — clean genetic epistasis in vivo with defined phenotypic readouts, epistasis with ApcMin","pmids":["19738063"],"is_preprint":false},{"year":2010,"finding":"EphB4 on tumor cells mediates site-specific metastatic dissemination by direct adhesive interaction with ephrin-B2 on endothelial cells; this was confirmed by atomic force microscopy at the single-cell level. The full intracellular domain (kinase activity) is required for organ-specific homing in vivo, as truncated EphB4 lacking the cytoplasmic domain does not promote metastatic dissemination.","method":"Atomic force microscopy (force spectroscopy); luciferase-based in vivo tumor cell trafficking; EphB4 truncation constructs; blocking with soluble EphB4-Fc","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1-2 — direct biophysical measurement of single-cell adhesion combined with in vivo trafficking and domain deletion experiments","pmids":["21047731"],"is_preprint":false},{"year":2010,"finding":"EphB4 forward kinase signaling is required for VEGF-driven angiogenesis; the specific small-molecule kinase inhibitor NVP-BHG712 inhibits EphB4 kinase activity at low nanomolar concentrations in cells, blocks EphB4 autophosphorylation in tissues after oral administration, and inhibits VEGF-induced vessel formation in vivo without directly affecting VEGFR kinase activity, demonstrating cross-talk between EphB4 and VEGFR signaling during angiogenesis.","method":"Biochemical kinase assay; cellular phosphorylation assay; kinase selectivity profiling; in vivo VEGF-driven angiogenesis model; pharmacokinetic analysis","journal":"Angiogenesis","confidence":"High","confidence_rationale":"Tier 1 — selective small-molecule inhibitor with biochemical validation and in vivo mechanistic dissection of EphB4 forward signaling","pmids":["20803239"],"is_preprint":false},{"year":2012,"finding":"EphB4 has dual roles in cancer depending on ligand availability: overexpressed EphB4 in the absence of ephrin-B2 promotes anchorage-independent growth, migration, and invasion (ligand-independent tumor promotion); upon ephrin-B2 stimulation, EphB4 is internalized and degraded via a phospho-ERK1/2-dependent mechanism, reducing proliferation and increasing caspase-3/7 activity (ligand-dependent tumor suppression).","method":"Overexpression in prostate cancer and mammary epithelial cell lines; ephrin-B2-Fc stimulation; anchorage-independent growth assay; ERK1/2 phosphorylation western blot; caspase activity assay; receptor internalization assay","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays distinguishing ligand-dependent vs. independent signaling, single lab","pmids":["22161689"],"is_preprint":false},{"year":2013,"finding":"EphB4 inhibition in esophageal cancer cells decreases phosphorylation of EphB4 and its downstream target p125FAK (focal adhesion kinase), and reduces cell migration, establishing FAK as a downstream effector of EphB4 forward signaling in cancer cells.","method":"Specific small-molecule EphB4 inhibitor; siRNA knockdown; cell migration assay; phosphotyrosine western blot; p125FAK immunoblot","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and genetic inhibition with defined downstream phosphorylation target, single lab","pmids":["23100466"],"is_preprint":false},{"year":2014,"finding":"RASA1 (p120RasGAP) functions as a critical effector downstream of EPHB4 in endothelial cells to suppress mTORC1 activity; EPHB4 recruits RASA1 directly, and this interaction is required for normal blood vessel formation. Loss of EPHB4 or RASA1 in zebrafish leads to robustly over-activated mTORC1, and pharmacological mTORC1 inhibition rescues vascular defects in EPHB4-deficient animals, establishing the EPHB4/RASA1/mTORC1 signaling axis.","method":"Zebrafish genetic models; engineered EPHB4 receptors with altered RASA1 binding; rescue experiments; mTORC1 activity assay; pharmacological mTORC1 inhibition; patient AVM tissue analysis (phospho-S6 staining)","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — genetic epistasis, engineered receptor constructs, pharmacological rescue, and patient tissue validation establishing the EPHB4/RASA1/mTORC1 axis","pmids":["24837431"],"is_preprint":false},{"year":2014,"finding":"PDGFRβ can activate EphB4 in a ligand-independent manner in rhabdomyosarcoma cells via PDGF ligand, converging on AKT and ERK1/2 signaling; conversely, EphB4 activation by its cognate ligand EphrinB2 does not activate PDGFRβ but instead paradoxically induces apoptosis, identifying EphB4 as a bivalent signaling node.","method":"Unbiased tyrosine kinome RNAi screen; co-immunoprecipitation; phospho-AKT/ERK western blot; apoptosis assay; dasatinib treatment in vitro and in vivo","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — unbiased screen validated by reciprocal co-IP and pharmacological dissection with defined downstream signaling readouts","pmids":["24733895"],"is_preprint":false},{"year":2015,"finding":"EphB4 functions as an alternative erythropoietin (Epo) receptor that triggers downstream STAT3 signaling upon Epo binding, promoting tumor growth and progression independently of the canonical EpoR.","method":"Receptor identification experiments; STAT3 phosphorylation assay upon rhEpo stimulation; EphB4 knockdown/overexpression in cancer cell lines; in vivo tumor growth assays","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 — novel receptor function identified with defined downstream pathway (STAT3), single lab","pmids":["26481148"],"is_preprint":false},{"year":2016,"finding":"EPHB4 regulates hematopoietic stem and progenitor cell (HSPC) mobilization from bone marrow through signaling interactions with ephrin B2 on hematopoietic cells; blockade of EPHB4/ephrin B2 signaling reduces HSPC mobilization and myeloid cell trafficking to tumors.","method":"Mutually exclusive localization of EPHB4 in sinusoids vs. ephrin B2 in hematopoietic cells by immunostaining; pharmacological blockade of EPHB4/ephrin B2 in mice; HSPC mobilization quantification; tumor infiltration assays","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment linked to functional HSPC mobilization phenotype, single lab","pmids":["27820703"],"is_preprint":false},{"year":2017,"finding":"Loss-of-function mutations in EPHB4 cause capillary malformation–arteriovenous malformation type 2 (CM-AVM2); in vitro expression of multiple patient missense mutations confirmed loss of EPHB4 kinase function; RASA1 (p120RasGAP), a direct effector of EPHB4, links this to deregulation of the RAS-ERK signaling pathway.","method":"Whole-exome sequencing; in vitro expression and kinase activity assay of mutant proteins; genetic linkage; patient cohort screening","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1-2 — functional validation of mutations in vitro combined with genetic linkage, multiple families and mutations","pmids":["28687708"],"is_preprint":false},{"year":2018,"finding":"A heterozygous EPHB4 splice-site mutation causing retention of a 12-bp intron reduces EPHB4 tyrosine phosphorylation (loss of function), leads to lymphatic vessel misbranching and developmental defects in zebrafish, and activates mTORC1 signaling; rescue with mTOR inhibitors or RAS-MAPK inhibitors restores normal vessel development.","method":"Whole exome sequencing; RNA-Seq splice analysis; transient co-expression of mutant/WT EPHB4 with phosphorylation assay; zebrafish morpholino; immunoblot for mTORC1 activity; pharmacological rescue; EPHB4 knock-in in HEK293T cells","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including in vitro kinase assay, zebrafish rescue, and cell-based knock-in confirming EPHB4→mTORC1 axis","pmids":["29905864"],"is_preprint":false},{"year":2019,"finding":"Inducible, endothelial-cell-specific deletion of EphB4 in adult mice causes rupturing of cardiac capillaries, cardiomyocyte hypertrophy, and pathological cardiac remodeling; mechanistically, EphB4 controls caveolae function, cell-cell adhesion under mechanical stress, and lipid transport specifically in cardiac (but not skeletal muscle) capillaries.","method":"Inducible endothelial-specific Ephb4 knockout mice; cardiac histology and electron microscopy; caveolae functional analysis; cell-cell adhesion assay under flow; lipid transport assay; cultured endothelial cells","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — inducible cell-specific KO with multiple mechanistic readouts (caveolae, adhesion, lipid transport), organ-specific phenotype characterized","pmids":["31782728"],"is_preprint":false},{"year":2019,"finding":"EPHB4 inhibition in prostate cancer cells reduces GLUT3 expression, impairs glucose uptake and lowers cellular ATP, activating endoplasmic reticulum stress and immunogenic cell death (eIF2α phosphorylation, surface calreticulin, HMGB1/ATP release); this is linked to MYC downregulation via the SRC/p38 MAPK/4EBP1 signaling cascade.","method":"EPHB4 inhibition (small molecule and genetic); glucose uptake assay; ATP measurement; ER stress markers (eIF2α phosphorylation, calreticulin); HMGB1/ATP release assays; MYC western blot; SRC/p38/4EBP1 pathway analysis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — multiple mechanistic readouts linking EPHB4 to metabolic and ER stress pathways, single lab","pmids":["31641103"],"is_preprint":false},{"year":2020,"finding":"EphrinB2/EphB4 signaling controls lymphatic endothelial cell junction stability by regulating junctional localization of the tight junction protein CLDN5 and cytoskeletal contractility via Rac1/Rho signaling; conditional gene deletion in mice showed this is dispensable for blood but required for lymphatic endothelial barrier function.","method":"Conditional gene deletion in mice (endothelial-specific); primary human lymphatic endothelial cells; immunofluorescence for CLDN5 localization; Rac1/Rho activity assays; junctional integrity functional assay","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — genetic deletion with mechanistic pathway (CLDN5/Rac1/Rho) validated in both mouse and human primary cells","pmids":["32897857"],"is_preprint":false},{"year":2021,"finding":"Mutations in EPHB4 cause primary venous valve aplasia in humans; conditional deletion of Ephb4 in mice disrupts valve-forming endothelial cell organization, reorientation, polarity, elongation, and proliferation, and loss of ephrinB2 disrupts junctional expression of connexin37 and connexin43 around reorienting valve-forming cells.","method":"Quantitative ultrasound in patients; conditional Ephb4 and Efnb2 knockout mice; GFP reporter for expression; immunostaining for connexin37/43, cell polarity, and proliferation markers","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 — genetic mouse models with mechanistic cellular readouts correlated with human genetic disease","pmids":["34403370"],"is_preprint":false},{"year":2022,"finding":"EphB4 binds directly to the insulin receptor (InsR); this interaction is markedly enhanced by insulin and facilitates clathrin-mediated InsR endocytosis and lysosomal degradation via an AP2 complex-binding motif in EphB4; hepatic EphB4 overexpression decreases InsR levels and increases insulin resistance in mice, while EphB4 inhibition improves insulin resistance in obese mice.","method":"Co-immunoprecipitation of EphB4 and InsR; AP2 motif mutation analysis; clathrin-mediated endocytosis assay; lysosomal degradation assay; hepatic overexpression and genetic/pharmacological inhibition in mice; glucose tolerance and insulin resistance tests","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding demonstrated by Co-IP, mechanism (AP2/clathrin/lysosome) confirmed by domain mutation and pathway inhibition, validated in vivo","pmids":["36131205"],"is_preprint":false},{"year":2022,"finding":"EPHB4 is required for export of collagen IV from the endoplasmic reticulum in vascular endothelial cells; loss of endothelial EPHB4 causes collagen IV accumulation in the ER, leading to EC apoptosis and defective angiogenesis; this function is independent of physical interaction with RASA1 but requires EPHB4 kinase activity, and can be rescued by drugs promoting collagen IV ER export or inhibiting Ras signaling.","method":"Induced EC-specific Ephb4 knockout mice; confocal imaging of collagen IV in ER; apoptosis assays; EPHB4 mutant knock-in (RASA1 binding-deficient); pharmacological rescue with ER export promoters and Ras pathway inhibitors","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1-2 — inducible EC-specific KO, domain-specific mutant knock-in, pharmacological rescue with multiple agents, mechanistically rigorous","pmids":["35015735"],"is_preprint":false},{"year":2022,"finding":"EphB4 acts as a tumor suppressor in head and neck squamous cell carcinoma: loss of EphB4 intracellular domain on cancer cells accelerates tumor growth and angiogenesis with compensatory upregulation of EphA4 and increased regulatory T cell infiltration; ephrinB2 knockout on cancer cells and vasculature produces maximal tumor reduction and vascular normalization, establishing ephrinB2 as a tumor promoter and EphB4 as a tumor suppressor in this context.","method":"Genetically engineered mice; EphB4 and ephrinB2 knockout; recombinant constructs; pharmacologic agonists and antagonists; tumor immune microenvironment analysis; EphA4 expression analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological manipulations in genetically engineered mice with defined mechanistic findings, single well-controlled study","pmids":["35725568"],"is_preprint":false},{"year":2002,"finding":"EphB4 signaling accelerates differentiation of human hematopoietic progenitor cells in a non-lineage-restricted manner, but preferentially promotes megakaryocytic and erythroid differentiation; effects are abrogated by mutations in select EphB4 tyrosine residues or by genistein (tyrosine kinase inhibitor), establishing tyrosine kinase activity and specific phosphorylation sites as required for these effects.","method":"Ectopic EphB4 expression in hematopoietic cell lines and cord blood CD34+ cells; site-directed mutagenesis of tyrosine residues; genistein inhibition; colony-forming and LTC-IC assays; differentiation marker expression","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis of tyrosine phosphorylation sites combined with functional differentiation assays, single lab","pmids":["11929761"],"is_preprint":false},{"year":2022,"finding":"EphB4 in colorectal cancer liver metastases interacts with EphrinB2 via forward signaling to enhance LDLR-mediated cholesterol uptake by promoting STAT3 phosphorylation which drives LDLR transcription; blocking the EFNB2/EphB4 axis reduces LDLR expression and cholesterol uptake in liver metastasis.","method":"In vitro and in vivo metastasis models; STAT3 phosphorylation assay; LDLR expression analysis; cholesterol uptake assay; LDLR rescue experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — defined signaling axis (EFNB2/EPHB4→STAT3→LDLR→cholesterol) with in vitro and in vivo validation, single lab","pmids":["36376513"],"is_preprint":false}],"current_model":"EphB4 is a transmembrane receptor tyrosine kinase that binds ephrin-B2 on adjacent cells to initiate bidirectional (forward through EphB4 kinase and reverse through ephrin-B2) contact-dependent signaling, governing arteriovenous endothelial cell identity and sorting, vascular/lymphatic morphogenesis and integrity (via Rho/Rac, caveolae, and CLDN5 junctional mechanisms), bone homeostasis (coupling osteoblast differentiation via forward signaling to osteoclast suppression of NFATc1 via reverse signaling), and tumor cell behavior (promoting migration through RhoA-mediated actin reorganization and survival via AKT/PI3K; alternatively acting as a tumor suppressor when ligand-activated); upstream, EphB4 recruits RASA1 to suppress mTORC1 in endothelial cells, facilitates collagen IV ER export required for angiogenesis, and in hepatocytes couples insulin-stimulated AP2-clathrin-mediated endocytosis of the insulin receptor to lysosomal degradation, thereby regulating systemic insulin sensitivity."},"narrative":{"teleology":[{"year":1994,"claim":"Establishing that EphB4 (HTK) possesses intrinsic tyrosine kinase activity and autophosphorylation capacity answered the foundational question of whether this orphan receptor signals through catalytic activity.","evidence":"In vitro kinase assay with purified protein and agonistic antibody stimulation in transfected NIH3T3 cells","pmids":["8188704"],"confidence":"High","gaps":["Cognate ligand not yet identified","No downstream effectors known","No in vivo function established"]},{"year":1999,"claim":"Demonstrating that EphB4 knockout phenocopies ephrin-B2 knockout — with selective venous expression of EphB4 — established ephrin-B2 as the cognate ligand and proved that bidirectional ephrinB2/EphB4 signaling is required for angiogenesis and arteriovenous identity.","evidence":"Targeted gene knockout mice with comparative phenotypic analysis between EphB4-null and ephrin-B2-null embryos","pmids":["10518221"],"confidence":"High","gaps":["Forward vs. reverse signaling contributions not individually resolved","Downstream intracellular effectors unknown"]},{"year":2003,"claim":"Dissecting forward versus reverse signaling showed they have non-overlapping functions: EphB4 forward signaling inhibits endothelial adhesion while reverse signaling through ephrin-B2 does not, clarifying how bidirectionality produces asymmetric cell behaviors at arteriovenous boundaries.","evidence":"Adhesion and migration assays with sorted primary endothelial cells using immobilized Fc-fusion proteins","pmids":["12588758"],"confidence":"Medium","gaps":["Signaling intermediates downstream of forward signaling not identified","In vivo validation of adhesion phenotype lacking"]},{"year":2004,"claim":"Multiple studies established that EphB4 kinase activity is required for migration inhibition and that kinase-dead EphB4 can still drive angiogenesis in vivo through reverse ephrin-B2 signaling, resolving that the extracellular domain alone is sufficient for reverse but not forward signaling outputs.","evidence":"Kinase-dead and truncated EphB4 constructs in cell migration assays and xenograft models; pharmacological kinase inhibition","pmids":["15067119","14672701"],"confidence":"Medium","gaps":["Specific kinase substrates not identified","Mechanism of reverse signaling transduction through ephrin-B2 not defined"]},{"year":2006,"claim":"A high-resolution crystal structure of the EphB4 ligand-binding domain revealed the hydrophobic cleft for ephrin-B2 engagement, providing the first atomic-level understanding of receptor-ligand specificity and enabling rational inhibitor design.","evidence":"X-ray crystallography at 1.65 Å with ITC validation of peptide binding determinants","pmids":["16472751"],"confidence":"High","gaps":["Full ectodomain complex with ephrin-B2 not yet solved","No structure of the kinase domain"]},{"year":2006,"claim":"Three concurrent discoveries expanded EphB4's functional repertoire beyond vasculature: forward signaling through EphB4 enhances osteoblast differentiation while reverse signaling suppresses osteoclastogenesis via NFATc1; EphB4 promotes melanoma migration via RhoA-mediated actin reorganization; and EphB4 sustains breast cancer cell survival through PI3K/AKT, establishing kinase-dependent downstream effector pathways.","evidence":"Transgenic EphB4 overexpression in osteoblasts with bone histomorphometry; dominant-negative RhoA and kinase-dead constructs in melanoma cells; siRNA knockdown with caspase and AKT assays in breast cancer cells","pmids":["16890539","16950769","16816380"],"confidence":"High","gaps":["Direct kinase substrates mediating RhoA activation unknown","Whether PI3K/AKT activation is direct or indirect unresolved"]},{"year":2008,"claim":"Genetic lineage tracing showed that ephrinB2/EphB4 sorts arterial and venous endothelial cells into correct vessels — a function mechanistically distinct from Notch-mediated control of arterial-venous proportions — clarifying the specific developmental role of this receptor pair.","evidence":"Mouse genetic loss-of-function with endothelial cell lineage tracing, compared with Notch gain/loss-of-function","pmids":["18952909"],"confidence":"High","gaps":["Cell-autonomous sorting mechanism not molecularly defined","Whether sorting requires kinase activity or reverse signaling not resolved"]},{"year":2009,"claim":"Discovery that EphB4 inhibits integrin-mediated adhesion in a ligand-independent, kinase-dependent manner — reducing β1-integrin levels — revealed a constitutive signaling mode independent of ephrin-B2 engagement.","evidence":"siRNA, overexpression, and ephrin-binding-deficient point mutants with adhesion/spreading assays and β1-integrin western blots","pmids":["19552627"],"confidence":"High","gaps":["Mechanism of β1-integrin downregulation not elucidated","Whether ligand-independent activity operates in normal physiology or only in overexpression contexts"]},{"year":2009,"claim":"EphB4 heterozygous inactivation in ApcMin mice accelerated intestinal tumorigenesis, establishing EphB4 as a haploinsufficient tumor suppressor in the intestine and showing its context-dependent oncogenic versus tumor-suppressive behavior.","evidence":"Genetic epistasis (ApcMin × EphB4+/−); tumor burden, invasion assays, xenograft models","pmids":["19738063"],"confidence":"High","gaps":["Tumor-suppressive mechanism downstream of EphB4 not molecularly defined","Whether ligand-dependent activation is required for suppressor function unclear"]},{"year":2012,"claim":"Resolving the dual-role paradox: in the absence of ephrin-B2, overexpressed EphB4 promotes anchorage-independent growth; upon ligand stimulation, EphB4 is internalized and degraded via ERK1/2-dependent mechanisms, switching to tumor suppression — explaining how the same receptor can be oncogenic or suppressive depending on microenvironmental context.","evidence":"Ligand-stimulated vs. unstimulated EphB4 overexpression; receptor internalization, ERK1/2 phosphorylation, caspase-3/7 activity in prostate and mammary cell lines","pmids":["22161689"],"confidence":"Medium","gaps":["Ubiquitin ligase or trafficking machinery for ligand-induced degradation not identified","Not validated in vivo"]},{"year":2014,"claim":"Identification of RASA1 as a direct effector recruited by EphB4 to suppress mTORC1 established the first complete signaling axis (EphB4→RASA1→mTORC1) for vascular development, and pharmacological mTORC1 inhibition rescued EphB4-deficient vascular defects, providing therapeutic proof-of-concept.","evidence":"Zebrafish genetics with engineered RASA1-binding-deficient EPHB4; mTORC1 activity assays; rapamycin rescue; patient AVM tissue phospho-S6 staining","pmids":["24837431"],"confidence":"High","gaps":["Whether RASA1 acts via Ras-GAP activity or a GAP-independent mechanism on mTORC1 not fully resolved","Mammalian genetic validation of the full axis incomplete at this point"]},{"year":2017,"claim":"Discovery that loss-of-function EPHB4 mutations cause CM-AVM2 in humans — with in vitro confirmation of kinase loss — established the first Mendelian disease caused by EPHB4 deficiency and linked it to the RASA1-RAS-ERK pathway.","evidence":"Whole-exome sequencing in multiple families; in vitro kinase activity assays of patient missense mutations","pmids":["28687708"],"confidence":"High","gaps":["Somatic second-hit mechanism not demonstrated","Genotype-phenotype correlations across mutation types not established"]},{"year":2019,"claim":"Inducible endothelial-specific EphB4 deletion in adults revealed organ-specific (cardiac) requirements for caveolae function, cell-cell adhesion under mechanical stress, and lipid transport, expanding EphB4's role from development to adult tissue homeostasis.","evidence":"Inducible EC-specific Ephb4 knockout mice; electron microscopy of caveolae; adhesion under flow; lipid transport assays","pmids":["31782728"],"confidence":"High","gaps":["Why cardiac but not skeletal muscle capillaries are affected is unexplained","Direct molecular link between EphB4 and caveolae biogenesis unknown"]},{"year":2020,"claim":"EphrinB2/EphB4 signaling was shown to maintain lymphatic endothelial barrier function by controlling CLDN5 junctional localization through Rac1/Rho, establishing a mechanistic link to lymphatic-specific (not blood vascular) integrity.","evidence":"Conditional endothelial gene deletion in mice; CLDN5 immunofluorescence; Rac1/Rho activity assays in primary human lymphatic endothelial cells","pmids":["32897857"],"confidence":"High","gaps":["How EphB4 selectively controls Rac1 vs. Rho balance in lymphatic but not blood endothelium not resolved","Direct phosphorylation targets linking EphB4 to CLDN5 trafficking unknown"]},{"year":2021,"claim":"Mutations in EPHB4 were shown to cause primary venous valve aplasia, with mechanistic dissection revealing that EphB4 controls valve-forming endothelial cell reorientation, polarity, and connexin37/43 junctional expression, expanding its disease spectrum beyond CM-AVM2.","evidence":"Human patient ultrasound; conditional Ephb4 and Efnb2 knockout mice; connexin37/43 immunostaining; cell polarity markers","pmids":["34403370"],"confidence":"High","gaps":["Whether valve aplasia results from forward signaling, reverse signaling, or both is not resolved","Downstream pathway from EphB4 to connexin expression not defined"]},{"year":2022,"claim":"Four studies in 2022 greatly expanded the mechanistic scope: EphB4 directly binds the insulin receptor and promotes its AP2/clathrin-mediated endocytosis and lysosomal degradation in hepatocytes, regulating systemic insulin sensitivity; EphB4 kinase activity is required for collagen IV ER export independent of RASA1 binding; EphB4 forward signaling acts as a tumor suppressor in head-and-neck cancer; and EphB4/ephrinB2 promotes STAT3-driven LDLR transcription enhancing cholesterol uptake in liver metastases.","evidence":"Co-IP of EphB4/InsR with AP2 motif mutagenesis and in vivo glucose tolerance tests; EC-specific Ephb4 KO with RASA1-binding-deficient knock-in and pharmacological ER export rescue; genetically engineered mouse tumor models; STAT3/LDLR pathway analysis in metastasis models","pmids":["36131205","35015735","35725568","36376513"],"confidence":"High","gaps":["Whether EphB4-InsR interaction requires ephrin-B2 or is ligand-independent in vivo","Kinase substrate mediating collagen IV ER export not identified","Mechanism by which EphB4 activates STAT3 for LDLR transcription not fully dissected"]},{"year":null,"claim":"Key unresolved questions include: the identity of direct EphB4 kinase substrates that mediate RhoA activation, caveolae regulation, and collagen IV ER export; the structural basis for EphB4's interaction with non-canonical ligands such as Epo and the insulin receptor; and how cell-type-specific signaling outputs (cardiac vs. lymphatic vs. hepatic) are determined.","evidence":"","pmids":[],"confidence":"Low","gaps":["No direct kinase substrate identified for most downstream phenotypes","Full-length EphB4 kinase domain structure not solved","Cell-type-specific signaling determinants remain undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,8,14,11]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[17,27]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[27]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,13,23]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[28]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,7,8,9,17,18,25]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,10,26]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[17,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,12,15,29]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[27]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[27,31]}],"complexes":[],"partners":["EFNB2","RASA1","INSR","RHOA","PDGFRB","CLDN5","SDC1"],"other_free_text":[]},"mechanistic_narrative":"EphB4 is a transmembrane receptor tyrosine kinase that, through bidirectional signaling with its cognate ligand ephrin-B2 on adjacent cells, governs arteriovenous endothelial identity, vascular and lymphatic morphogenesis, bone homeostasis, hematopoietic progenitor mobilization, and tumor cell behavior. Forward signaling through the EphB4 kinase domain recruits RASA1 to suppress mTORC1 in endothelial cells, activates RhoA to reorganize the actin cytoskeleton, regulates collagen IV ER export required for angiogenesis, controls caveolae function and CLDN5-dependent lymphatic junctional integrity via Rac1/Rho, and in hepatocytes couples insulin receptor internalization through an AP2-clathrin pathway to lysosomal degradation, thereby modulating systemic insulin sensitivity [PMID:24837431, PMID:16950769, PMID:35015735, PMID:32897857, PMID:31782728, PMID:36131205]. Loss-of-function mutations in EPHB4 cause capillary malformation–arteriovenous malformation type 2 (CM-AVM2) and primary venous valve aplasia in humans [PMID:28687708, PMID:34403370]. In cancer, EphB4 exhibits context-dependent dual roles: ligand-independent kinase activity promotes survival via PI3K/AKT and migration via RhoA/FAK, whereas ephrin-B2-stimulated forward signaling triggers receptor internalization/degradation and can suppress tumor growth, consistent with its tumor-suppressor function in intestinal and head-and-neck carcinogenesis [PMID:22161689, PMID:19738063, PMID:35725568]."},"prefetch_data":{"uniprot":{"accession":"P54760","full_name":"Ephrin type-B receptor 4","aliases":["Hepatoma transmembrane kinase","Tyrosine-protein kinase TYRO11"],"length_aa":987,"mass_kda":108.3,"function":"Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Together with its cognate ligand/functional ligand EFNB2 it is involved in the regulation of cell adhesion and migration, and plays a central role in heart morphogenesis, angiogenesis and blood vessel remodeling and permeability. EPHB4-mediated forward signaling controls cellular repulsion and segregation from EFNB2-expressing cells","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P54760/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EPHB4","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/EPHB4","total_profiled":1310},"omim":[{"mim_id":"618196","title":"CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION 2; CMAVM2","url":"https://www.omim.org/entry/618196"},{"mim_id":"617300","title":"LYMPHATIC MALFORMATION 7; LMPHM7","url":"https://www.omim.org/entry/617300"},{"mim_id":"608354","title":"CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION 1; CMAVM1","url":"https://www.omim.org/entry/608354"},{"mim_id":"604674","title":"HES-RELATED FAMILY bHLH TRANSCRIPTION FACTOR WITH YRPW MOTIF 2; HEY2","url":"https://www.omim.org/entry/604674"},{"mim_id":"602757","title":"EPHRIN RECEPTOR EphB6; EPHB6","url":"https://www.omim.org/entry/602757"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/EPHB4"},"hgnc":{"alias_symbol":["Tyro11"],"prev_symbol":["HTK"]},"alphafold":{"accession":"P54760","domains":[{"cath_id":"2.60.120.260","chopping":"15-195","consensus_level":"high","plddt":86.2931,"start":15,"end":195},{"cath_id":"2.60.40.1770","chopping":"199-255","consensus_level":"medium","plddt":85.1328,"start":199,"end":255},{"cath_id":"2.60.40.10","chopping":"327-428","consensus_level":"medium","plddt":90.4265,"start":327,"end":428},{"cath_id":"2.60.40.10","chopping":"439-460_469-524","consensus_level":"high","plddt":86.9651,"start":439,"end":524},{"cath_id":"3.30.200.20","chopping":"592-693","consensus_level":"high","plddt":87.4689,"start":592,"end":693},{"cath_id":"1.10.510.10","chopping":"698-883","consensus_level":"high","plddt":86.7886,"start":698,"end":883},{"cath_id":"1.10.150.50","chopping":"907-969","consensus_level":"high","plddt":86.6022,"start":907,"end":969}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P54760","model_url":"https://alphafold.ebi.ac.uk/files/AF-P54760-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P54760-F1-predicted_aligned_error_v6.png","plddt_mean":82.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EPHB4","jax_strain_url":"https://www.jax.org/strain/search?query=EPHB4"},"sequence":{"accession":"P54760","fasta_url":"https://rest.uniprot.org/uniprotkb/P54760.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P54760/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P54760"}},"corpus_meta":[{"pmid":"16890539","id":"PMC_16890539","title":"Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis.","date":"2006","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16890539","citation_count":596,"is_preprint":false},{"pmid":"10518221","id":"PMC_10518221","title":"Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10518221","citation_count":564,"is_preprint":false},{"pmid":"15067119","id":"PMC_15067119","title":"Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15067119","citation_count":211,"is_preprint":false},{"pmid":"28687708","id":"PMC_28687708","title":"Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling.","date":"2017","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/28687708","citation_count":205,"is_preprint":false},{"pmid":"16816380","id":"PMC_16816380","title":"Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.","date":"2006","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16816380","citation_count":165,"is_preprint":false},{"pmid":"16322467","id":"PMC_16322467","title":"The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16322467","citation_count":136,"is_preprint":false},{"pmid":"19366806","id":"PMC_19366806","title":"Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19366806","citation_count":120,"is_preprint":false},{"pmid":"17483308","id":"PMC_17483308","title":"Paradoxes of the EphB4 receptor in cancer.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17483308","citation_count":113,"is_preprint":false},{"pmid":"15153337","id":"PMC_15153337","title":"Inhibition of tumor growth and angiogenesis by soluble EphB4.","date":"2004","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15153337","citation_count":108,"is_preprint":false},{"pmid":"15029258","id":"PMC_15029258","title":"Expression of Ephb2 and Ephb4 in breast carcinoma.","date":"2004","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/15029258","citation_count":104,"is_preprint":false},{"pmid":"20803239","id":"PMC_20803239","title":"The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.","date":"2010","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20803239","citation_count":104,"is_preprint":false},{"pmid":"18952909","id":"PMC_18952909","title":"Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis.","date":"2008","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18952909","citation_count":98,"is_preprint":false},{"pmid":"26481148","id":"PMC_26481148","title":"Erythropoietin Stimulates Tumor Growth via EphB4.","date":"2015","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/26481148","citation_count":86,"is_preprint":false},{"pmid":"16950769","id":"PMC_16950769","title":"The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16950769","citation_count":84,"is_preprint":false},{"pmid":"19597185","id":"PMC_19597185","title":"The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19597185","citation_count":82,"is_preprint":false},{"pmid":"25586589","id":"PMC_25586589","title":"Erythropoietin promotes bone formation through EphrinB2/EphB4 signaling.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/25586589","citation_count":79,"is_preprint":false},{"pmid":"12588758","id":"PMC_12588758","title":"Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12588758","citation_count":76,"is_preprint":false},{"pmid":"16472751","id":"PMC_16472751","title":"Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity.","date":"2006","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/16472751","citation_count":75,"is_preprint":false},{"pmid":"8188704","id":"PMC_8188704","title":"Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8188704","citation_count":74,"is_preprint":false},{"pmid":"29905864","id":"PMC_29905864","title":"Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29905864","citation_count":73,"is_preprint":false},{"pmid":"20133814","id":"PMC_20133814","title":"Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth.","date":"2010","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20133814","citation_count":71,"is_preprint":false},{"pmid":"16615113","id":"PMC_16615113","title":"EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16615113","citation_count":67,"is_preprint":false},{"pmid":"24837431","id":"PMC_24837431","title":"RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24837431","citation_count":65,"is_preprint":false},{"pmid":"23844053","id":"PMC_23844053","title":"The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23844053","citation_count":62,"is_preprint":false},{"pmid":"12051776","id":"PMC_12051776","title":"A role of EphB4 receptor and its ligand, ephrin-B2, in erythropoiesis.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12051776","citation_count":60,"is_preprint":false},{"pmid":"19950015","id":"PMC_19950015","title":"Communication between ephrinB2 and EphB4 within the osteoblast lineage.","date":"2010","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/19950015","citation_count":57,"is_preprint":false},{"pmid":"19738063","id":"PMC_19738063","title":"The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19738063","citation_count":56,"is_preprint":false},{"pmid":"18231102","id":"PMC_18231102","title":"Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.","date":"2008","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18231102","citation_count":55,"is_preprint":false},{"pmid":"22161689","id":"PMC_22161689","title":"Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22161689","citation_count":55,"is_preprint":false},{"pmid":"28993206","id":"PMC_28993206","title":"Targeting receptor tyrosine kinase EphB4 in cancer therapy.","date":"2017","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/28993206","citation_count":54,"is_preprint":false},{"pmid":"32407961","id":"PMC_32407961","title":"Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32407961","citation_count":53,"is_preprint":false},{"pmid":"19552627","id":"PMC_19552627","title":"Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19552627","citation_count":52,"is_preprint":false},{"pmid":"27216867","id":"PMC_27216867","title":"EphrinB2/EphB4 pathway in postnatal angiogenesis: a potential therapeutic target for ischemic cardiovascular disease.","date":"2016","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27216867","citation_count":48,"is_preprint":false},{"pmid":"24677183","id":"PMC_24677183","title":"Ephrin B2/EphB4 mediates the actions of IGF-I signaling in regulating endochondral bone formation.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24677183","citation_count":48,"is_preprint":false},{"pmid":"32897857","id":"PMC_32897857","title":"EphrinB2-EphB4 signalling provides Rho-mediated homeostatic control of lymphatic endothelial cell junction integrity.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32897857","citation_count":47,"is_preprint":false},{"pmid":"31782728","id":"PMC_31782728","title":"Endothelial EphB4 maintains vascular integrity and transport function in adult heart.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31782728","citation_count":46,"is_preprint":false},{"pmid":"31641103","id":"PMC_31641103","title":"EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31641103","citation_count":46,"is_preprint":false},{"pmid":"15914639","id":"PMC_15914639","title":"Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy.","date":"2005","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/15914639","citation_count":45,"is_preprint":false},{"pmid":"23100466","id":"PMC_23100466","title":"Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23100466","citation_count":44,"is_preprint":false},{"pmid":"30894369","id":"PMC_30894369","title":"Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30894369","citation_count":44,"is_preprint":false},{"pmid":"23165754","id":"PMC_23165754","title":"EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair.","date":"2013","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/23165754","citation_count":44,"is_preprint":false},{"pmid":"24517927","id":"PMC_24517927","title":"Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.","date":"2014","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/24517927","citation_count":41,"is_preprint":false},{"pmid":"21047731","id":"PMC_21047731","title":"EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.","date":"2010","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/21047731","citation_count":41,"is_preprint":false},{"pmid":"17108150","id":"PMC_17108150","title":"Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.","date":"2006","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17108150","citation_count":41,"is_preprint":false},{"pmid":"15958611","id":"PMC_15958611","title":"Up-regulation of EphB4 in mesothelioma and its biological significance.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15958611","citation_count":40,"is_preprint":false},{"pmid":"32488576","id":"PMC_32488576","title":"The critical role of the interplays of EphrinB2/EphB4 and VEGF in the induction of angiogenesis.","date":"2020","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/32488576","citation_count":39,"is_preprint":false},{"pmid":"11929761","id":"PMC_11929761","title":"Receptor tyrosine kinase, EphB4 (HTK), accelerates differentiation of select human hematopoietic cells.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11929761","citation_count":39,"is_preprint":false},{"pmid":"27072105","id":"PMC_27072105","title":"EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer.","date":"2016","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27072105","citation_count":38,"is_preprint":false},{"pmid":"33085838","id":"PMC_33085838","title":"CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33085838","citation_count":37,"is_preprint":false},{"pmid":"33636580","id":"PMC_33636580","title":"Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer.","date":"2021","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33636580","citation_count":36,"is_preprint":false},{"pmid":"27820703","id":"PMC_27820703","title":"Sinusoidal ephrin receptor EPHB4 controls hematopoietic progenitor cell mobilization from bone marrow.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27820703","citation_count":35,"is_preprint":false},{"pmid":"16303978","id":"PMC_16303978","title":"Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization.","date":"2005","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/16303978","citation_count":35,"is_preprint":false},{"pmid":"30644610","id":"PMC_30644610","title":"Antitumor effects of circ-EPHB4 in hepatocellular carcinoma via inhibition of HIF-1α.","date":"2019","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30644610","citation_count":34,"is_preprint":false},{"pmid":"24733895","id":"PMC_24733895","title":"PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24733895","citation_count":33,"is_preprint":false},{"pmid":"29383777","id":"PMC_29383777","title":"Long noncoding RNA BC005927 upregulates EPHB4 and promotes gastric cancer metastasis under hypoxia.","date":"2018","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/29383777","citation_count":32,"is_preprint":false},{"pmid":"20850301","id":"PMC_20850301","title":"Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.","date":"2010","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/20850301","citation_count":32,"is_preprint":false},{"pmid":"26033476","id":"PMC_26033476","title":"EphB4 Expressing Stromal Cells Exhibit an Enhanced Capacity for Hematopoietic Stem Cell Maintenance.","date":"2015","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/26033476","citation_count":31,"is_preprint":false},{"pmid":"20682653","id":"PMC_20682653","title":"Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.","date":"2010","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20682653","citation_count":31,"is_preprint":false},{"pmid":"32801343","id":"PMC_32801343","title":"Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated β-catenin loss in hepatocellular carcinoma.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32801343","citation_count":30,"is_preprint":false},{"pmid":"15126321","id":"PMC_15126321","title":"Syndecan-1 up-regulated by ephrinB2/EphB4 plays dual roles in inflammatory angiogenesis.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15126321","citation_count":30,"is_preprint":false},{"pmid":"29700355","id":"PMC_29700355","title":"Claudin 11 regulates bone homeostasis via bidirectional EphB4-EphrinB2 signaling.","date":"2018","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29700355","citation_count":29,"is_preprint":false},{"pmid":"20031623","id":"PMC_20031623","title":"EPHB4 gene polymorphisms and risk of intracranial hemorrhage in patients with brain arteriovenous malformations.","date":"2009","source":"Circulation. Cardiovascular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20031623","citation_count":28,"is_preprint":false},{"pmid":"27273865","id":"PMC_27273865","title":"KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors.","date":"2016","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27273865","citation_count":28,"is_preprint":false},{"pmid":"36131205","id":"PMC_36131205","title":"Insulin induces insulin receptor degradation in the liver through EphB4.","date":"2022","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36131205","citation_count":27,"is_preprint":false},{"pmid":"35015735","id":"PMC_35015735","title":"Angiogenesis depends upon EPHB4-mediated export of collagen IV from vascular endothelial cells.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35015735","citation_count":27,"is_preprint":false},{"pmid":"19356789","id":"PMC_19356789","title":"Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.","date":"2009","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19356789","citation_count":26,"is_preprint":false},{"pmid":"29848571","id":"PMC_29848571","title":"Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29848571","citation_count":26,"is_preprint":false},{"pmid":"17454677","id":"PMC_17454677","title":"EphB4 expression along adult rat microvascular networks: EphB4 is more than a venous specific marker.","date":"2007","source":"Microcirculation (New York, N.Y. : 1994)","url":"https://pubmed.ncbi.nlm.nih.gov/17454677","citation_count":25,"is_preprint":false},{"pmid":"32286515","id":"PMC_32286515","title":"Dysregulation of the EphrinB2-EphB4 ratio in pediatric cerebral arteriovenous malformations is associated with endothelial cell dysfunction in vitro and functions as a novel noninvasive biomarker in patients.","date":"2020","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32286515","citation_count":25,"is_preprint":false},{"pmid":"23696610","id":"PMC_23696610","title":"EphrinB2-EphB4 signals regulate formation and maintenance of funnel-shaped valves in corneal lymphatic capillaries.","date":"2013","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/23696610","citation_count":25,"is_preprint":false},{"pmid":"19879134","id":"PMC_19879134","title":"Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.","date":"2009","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/19879134","citation_count":24,"is_preprint":false},{"pmid":"25191151","id":"PMC_25191151","title":"Arterial shear stress reduces eph-b4 expression in adult human veins.","date":"2014","source":"The Yale journal of biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25191151","citation_count":23,"is_preprint":false},{"pmid":"14672701","id":"PMC_14672701","title":"EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14672701","citation_count":23,"is_preprint":false},{"pmid":"37425367","id":"PMC_37425367","title":"Low-intensity pulsed ultrasound regulates osteoblast-osteoclast crosstalk via EphrinB2/EphB4 signaling for orthodontic alveolar bone remodeling.","date":"2023","source":"Frontiers in bioengineering and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37425367","citation_count":23,"is_preprint":false},{"pmid":"27726217","id":"PMC_27726217","title":"Low concentrations of TNF-α promote osteogenic differentiation via activation of the ephrinB2-EphB4 signalling pathway.","date":"2016","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/27726217","citation_count":23,"is_preprint":false},{"pmid":"23394931","id":"PMC_23394931","title":"Vascular endothelial growth factor-A inhibits EphB4 and stimulates delta-like ligand 4 expression in adult endothelial cells.","date":"2013","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/23394931","citation_count":23,"is_preprint":false},{"pmid":"20686847","id":"PMC_20686847","title":"Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer.","date":"2010","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20686847","citation_count":22,"is_preprint":false},{"pmid":"36376513","id":"PMC_36376513","title":"Adaptive activation of EFNB2/EPHB4 axis promotes post-metastatic growth of colorectal cancer liver metastases by LDLR-mediated cholesterol uptake.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36376513","citation_count":22,"is_preprint":false},{"pmid":"25473648","id":"PMC_25473648","title":"Compressive force regulates ephrinB2 and EphB4 in osteoblasts and osteoclasts contributing to alveolar bone resorption during experimental tooth movement.","date":"2014","source":"Korean journal of orthodontics","url":"https://pubmed.ncbi.nlm.nih.gov/25473648","citation_count":22,"is_preprint":false},{"pmid":"26264644","id":"PMC_26264644","title":"Specific photothermal therapy to the tumors with high EphB4 receptor expression.","date":"2015","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/26264644","citation_count":21,"is_preprint":false},{"pmid":"23211050","id":"PMC_23211050","title":"Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring.","date":"2012","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/23211050","citation_count":20,"is_preprint":false},{"pmid":"23269240","id":"PMC_23269240","title":"Reduced adult endothelial cell EphB4 function promotes venous remodeling.","date":"2012","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23269240","citation_count":20,"is_preprint":false},{"pmid":"35725568","id":"PMC_35725568","title":"EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35725568","citation_count":19,"is_preprint":false},{"pmid":"35163601","id":"PMC_35163601","title":"EphrinB2-EphB4 Signaling in Neurooncological Disease.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163601","citation_count":19,"is_preprint":false},{"pmid":"29296810","id":"PMC_29296810","title":"EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.","date":"2017","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/29296810","citation_count":19,"is_preprint":false},{"pmid":"35690294","id":"PMC_35690294","title":"ED-71 inhibited osteoclastogenesis by enhancing EphrinB2-EphB4 signaling between osteoclasts and osteoblasts in osteoporosis.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35690294","citation_count":19,"is_preprint":false},{"pmid":"25831049","id":"PMC_25831049","title":"Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25831049","citation_count":19,"is_preprint":false},{"pmid":"29369779","id":"PMC_29369779","title":"EphB4: A promising target for upper aerodigestive malignancies.","date":"2018","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29369779","citation_count":19,"is_preprint":false},{"pmid":"36632458","id":"PMC_36632458","title":"M6PR- and EphB4-Rich Exosomes Secreted by Serglycin-Overexpressing Esophageal Cancer Cells Promote Cancer Progression.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36632458","citation_count":18,"is_preprint":false},{"pmid":"24634162","id":"PMC_24634162","title":"Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot study.","date":"2014","source":"Head & neck","url":"https://pubmed.ncbi.nlm.nih.gov/24634162","citation_count":18,"is_preprint":false},{"pmid":"23138393","id":"PMC_23138393","title":"EphB4 is overexpressed in gliomas and promotes the growth of glioma cells.","date":"2012","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23138393","citation_count":18,"is_preprint":false},{"pmid":"27512150","id":"PMC_27512150","title":"EPHB4 Regulates Human Trophoblast Cell Line HTR-8/SVneo Function: Implications for the Role of EPHB4 in Preeclampsia.","date":"2016","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/27512150","citation_count":18,"is_preprint":false},{"pmid":"34403370","id":"PMC_34403370","title":"Mutations in EPHB4 cause human venous valve aplasia.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/34403370","citation_count":17,"is_preprint":false},{"pmid":"32006616","id":"PMC_32006616","title":"Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32006616","citation_count":17,"is_preprint":false},{"pmid":"32508946","id":"PMC_32508946","title":"Icariin Alleviates Glucocorticoid-Induced Osteoporosis through EphB4/Ephrin-B2 Axis.","date":"2020","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/32508946","citation_count":17,"is_preprint":false},{"pmid":"32989254","id":"PMC_32989254","title":"Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32989254","citation_count":17,"is_preprint":false},{"pmid":"30538561","id":"PMC_30538561","title":"Notch signaling promotes serrated neoplasia pathway in colorectal cancer through epigenetic modification of EPHB2 and EPHB4.","date":"2018","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/30538561","citation_count":17,"is_preprint":false},{"pmid":"34420849","id":"PMC_34420849","title":"Reconditioning of circulatory death hearts by ex-vivo machine perfusion with a novel HTK-N preservation solution.","date":"2021","source":"The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/34420849","citation_count":17,"is_preprint":false},{"pmid":"30944125","id":"PMC_30944125","title":"Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30944125","citation_count":16,"is_preprint":false},{"pmid":"28817624","id":"PMC_28817624","title":"EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28817624","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50321,"output_tokens":8385,"usd":0.138369},"stage2":{"model":"claude-opus-4-6","input_tokens":12144,"output_tokens":4346,"usd":0.254055},"total_usd":0.392424,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"EphB4 (originally cloned as HTK) is a transmembrane receptor tyrosine kinase of the EPH subfamily that autophosphorylates on tyrosine and exhibits intrinsic kinase activity in vitro; antibodies against its extracellular domain act as agonists inducing tyrosine phosphorylation in transfected cells.\",\n      \"method\": \"In vitro kinase assay with purified in vitro translated protein; immunoprecipitation; agonistic antibody stimulation in transfected NIH3T3 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning paper with in vitro kinase reconstitution and autophosphorylation assay\",\n      \"pmids\": [\"8188704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"EphB4 is selectively expressed on venous (not arterial) endothelial cells in embryos, and targeted loss-of-function of EphB4 phenocopies the ephrin-B2 knockout, demonstrating that ephrin-B2/EphB4 interactions are intrinsically required in vascular endothelial cells for angiogenesis via bidirectional signaling.\",\n      \"method\": \"Targeted gene knockout in mice; comparative phenotypic analysis with ephrin-B2 null mice; immunohistochemistry for expression pattern\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal genetic loss-of-function with clear phenotypic readout, replicated across two mutant lines\",\n      \"pmids\": [\"10518221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"EphB4 forward signaling (via its kinase domain activated by ephrin-B2) inhibits endothelial cell adhesion, whereas EphB4-mediated reverse signaling through ephrin-B2 does not inhibit adhesion; cell migration is inhibited on immobilized ephrin-B2-Fc but not on EphB4-Fc, demonstrating distinct functional roles of forward vs. reverse signaling in arterial-venous endothelial cell interactions.\",\n      \"method\": \"Cell adhesion and migration assays using sorted primary endothelial cells and cell lines treated with immobilized Fc-fusion proteins\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assays distinguishing forward vs. reverse signaling, single lab\",\n      \"pmids\": [\"12588758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"EphB4 on tumor cells promotes angiogenesis and tumor growth by interacting with ephrin-B2 on vascular endothelial cells; the extracellular domain of EphB4 attracts endothelial cells and stimulates endothelial cell invasion, survival, and proliferation in vitro, and EphB4 lacking the kinase domain (dominant negative) still promotes blood vessel enlargement in vivo via reverse ephrin-B2 signaling.\",\n      \"method\": \"Mouse xenograft model; in vitro endothelial cell migration/invasion/survival assays; EGFP-tagged kinase-dead EphB4 constructs\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — kinase-dead construct dissects forward vs. reverse signaling, in vitro and in vivo evidence\",\n      \"pmids\": [\"15067119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"EphB4 signaling mediates ephrinB2-induced inhibition of cell migration; EphB4 kinase activity is essential for this effect, as demonstrated by relief of migration inhibition upon treatment with the Src-family kinase inhibitor PP2 (which also inhibits EphB4 kinase).\",\n      \"method\": \"Cell migration assay in a system solely dependent on ephrinB2-EphB4 signaling; pharmacological kinase inhibition with PP2 and PD153035\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional migration assay with kinase inhibition demonstrating requirement for catalytic activity, single lab\",\n      \"pmids\": [\"14672701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Upon EphB4 activation by ephrinB2, syndecan-1 and syntenin are upregulated in EphB4-positive endothelial cells in a dose- and time-dependent manner; upregulated syndecan-1 can compete with FGFR for bFGF, suppressing angiogenesis in vitro, but heparanase (present in inflamed tissue) cleaves syndecan-1 and converts the inhibitory effect to an activating one in vivo.\",\n      \"method\": \"cDNA microarray followed by RT-PCR; in vitro angiogenesis assay; preclustered ephrinB2 stimulation of endothelial cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (microarray, RT-PCR, functional assay) identifying downstream targets, single lab\",\n      \"pmids\": [\"15126321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Crystal structure of the EphB4 ligand-binding domain in complex with an antagonist peptide at 1.65 Å resolution reveals the peptide occupies the hydrophobic cleft corresponding to the ephrin-B2 G-H loop binding site; specific residues in this cleft determine EphB4 ligand specificity, and isothermal titration calorimetry identified peptide residues critical for receptor binding.\",\n      \"method\": \"X-ray crystallography at 1.65 Å; isothermal titration calorimetry with truncated peptide variants\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with thermodynamic validation, defines molecular determinants of ligand specificity\",\n      \"pmids\": [\"16472751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis: reverse signaling through ephrinB2 (expressed by osteoclast precursors) suppresses osteoclast differentiation by inhibiting the c-Fos–NFATc1 cascade, while forward signaling through EphB4 (expressed by osteoblasts) enhances osteoblast differentiation; transgenic overexpression of EphB4 in osteoblasts increases bone mass.\",\n      \"method\": \"Gain- and loss-of-function mouse experiments; transgenic EphB4 overexpression; analysis of c-Fos and NFATc1 signaling; bone histomorphometry\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional pathway dissected with multiple genetic models and defined molecular cascades, highly cited foundational study\",\n      \"pmids\": [\"16890539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"EphB4 forward signaling promotes melanoma cell migration via activation of RhoA and consequent actin cytoskeleton reorganization; EphB4 kinase activity is required, as kinase-dead EphB4 inhibits migration and actin organization, and dominant negative RhoA blocks the pro-migratory effect of active EphB4.\",\n      \"method\": \"Overexpression/kinase-dead EphB4 constructs; dominant negative RhoA; cell migration assays; RhoA activity pull-down assay; actin cytoskeleton imaging\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple constructs and orthogonal assays establishing kinase-dependent RhoA-mediated mechanism\",\n      \"pmids\": [\"16950769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"EphB4 promotes breast cancer cell survival and acts as a survival factor; phosphorylation by its ligand EphrinB2 activates the PI3K/AKT pathway; EphB4 knockdown by siRNA induces apoptosis via caspase activation and sensitizes cells to TRAIL.\",\n      \"method\": \"siRNA knockdown; antisense oligonucleotides; cell viability and apoptosis assays; caspase activation assay; mouse xenograft model\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined pathway (AKT) and phenotypic readout, single lab\",\n      \"pmids\": [\"16816380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"EphrinB2/EphB4 signaling functions to sort arterial and venous endothelial cells into their respective vessels during angiogenesis; loss of ephrin B2 or EphB4 leads to mislocalization of venous-identity cells into the aorta, whereas Notch controls the relative size of arteries and veins by affecting arterial-to-venous endothelial cell proportions.\",\n      \"method\": \"Mouse genetic loss-of-function models; endothelial cell lineage tracing and localization analysis; comparison with Notch gain/loss-of-function\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with mechanistic distinction from Notch pathway, multiple mutant alleles\",\n      \"pmids\": [\"18952909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"EphB4 inhibits integrin-mediated cell-substrate adhesion, spreading, and migration in cancer cells in an ephrin-ligand-independent manner; this requires EphB4 kinase activity, and is associated with reduced β1-integrin protein levels. Mutations impairing ephrin binding do not affect this ligand-independent adhesion inhibition, demonstrating a constitutive, kinase-dependent function.\",\n      \"method\": \"siRNA knockdown; transient overexpression; single amino acid mutations impairing ephrin binding; cell adhesion/spreading/migration assays; western blotting for β1-integrin\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (siRNA, overexpression, binding-deficient mutants) establishing ligand-independent, kinase-dependent mechanism\",\n      \"pmids\": [\"19552627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"EphB4 has tumor suppressor activities in intestinal tumorigenesis; inactivation of a single EphB4 allele in ApcMin mice results in increased proliferation, larger and more numerous intestinal tumors, and a 25% shorter lifespan; loss of EPHB4 in colon cancer cells increases invasive potential through extracellular matrix.\",\n      \"method\": \"Genetic mouse model (ApcMin × EphB4 heterozygous knockout); in vitro invasion assay; gene expression profiling; xenograft model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic epistasis in vivo with defined phenotypic readouts, epistasis with ApcMin\",\n      \"pmids\": [\"19738063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"EphB4 on tumor cells mediates site-specific metastatic dissemination by direct adhesive interaction with ephrin-B2 on endothelial cells; this was confirmed by atomic force microscopy at the single-cell level. The full intracellular domain (kinase activity) is required for organ-specific homing in vivo, as truncated EphB4 lacking the cytoplasmic domain does not promote metastatic dissemination.\",\n      \"method\": \"Atomic force microscopy (force spectroscopy); luciferase-based in vivo tumor cell trafficking; EphB4 truncation constructs; blocking with soluble EphB4-Fc\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct biophysical measurement of single-cell adhesion combined with in vivo trafficking and domain deletion experiments\",\n      \"pmids\": [\"21047731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"EphB4 forward kinase signaling is required for VEGF-driven angiogenesis; the specific small-molecule kinase inhibitor NVP-BHG712 inhibits EphB4 kinase activity at low nanomolar concentrations in cells, blocks EphB4 autophosphorylation in tissues after oral administration, and inhibits VEGF-induced vessel formation in vivo without directly affecting VEGFR kinase activity, demonstrating cross-talk between EphB4 and VEGFR signaling during angiogenesis.\",\n      \"method\": \"Biochemical kinase assay; cellular phosphorylation assay; kinase selectivity profiling; in vivo VEGF-driven angiogenesis model; pharmacokinetic analysis\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — selective small-molecule inhibitor with biochemical validation and in vivo mechanistic dissection of EphB4 forward signaling\",\n      \"pmids\": [\"20803239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"EphB4 has dual roles in cancer depending on ligand availability: overexpressed EphB4 in the absence of ephrin-B2 promotes anchorage-independent growth, migration, and invasion (ligand-independent tumor promotion); upon ephrin-B2 stimulation, EphB4 is internalized and degraded via a phospho-ERK1/2-dependent mechanism, reducing proliferation and increasing caspase-3/7 activity (ligand-dependent tumor suppression).\",\n      \"method\": \"Overexpression in prostate cancer and mammary epithelial cell lines; ephrin-B2-Fc stimulation; anchorage-independent growth assay; ERK1/2 phosphorylation western blot; caspase activity assay; receptor internalization assay\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays distinguishing ligand-dependent vs. independent signaling, single lab\",\n      \"pmids\": [\"22161689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"EphB4 inhibition in esophageal cancer cells decreases phosphorylation of EphB4 and its downstream target p125FAK (focal adhesion kinase), and reduces cell migration, establishing FAK as a downstream effector of EphB4 forward signaling in cancer cells.\",\n      \"method\": \"Specific small-molecule EphB4 inhibitor; siRNA knockdown; cell migration assay; phosphotyrosine western blot; p125FAK immunoblot\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic inhibition with defined downstream phosphorylation target, single lab\",\n      \"pmids\": [\"23100466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RASA1 (p120RasGAP) functions as a critical effector downstream of EPHB4 in endothelial cells to suppress mTORC1 activity; EPHB4 recruits RASA1 directly, and this interaction is required for normal blood vessel formation. Loss of EPHB4 or RASA1 in zebrafish leads to robustly over-activated mTORC1, and pharmacological mTORC1 inhibition rescues vascular defects in EPHB4-deficient animals, establishing the EPHB4/RASA1/mTORC1 signaling axis.\",\n      \"method\": \"Zebrafish genetic models; engineered EPHB4 receptors with altered RASA1 binding; rescue experiments; mTORC1 activity assay; pharmacological mTORC1 inhibition; patient AVM tissue analysis (phospho-S6 staining)\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic epistasis, engineered receptor constructs, pharmacological rescue, and patient tissue validation establishing the EPHB4/RASA1/mTORC1 axis\",\n      \"pmids\": [\"24837431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PDGFRβ can activate EphB4 in a ligand-independent manner in rhabdomyosarcoma cells via PDGF ligand, converging on AKT and ERK1/2 signaling; conversely, EphB4 activation by its cognate ligand EphrinB2 does not activate PDGFRβ but instead paradoxically induces apoptosis, identifying EphB4 as a bivalent signaling node.\",\n      \"method\": \"Unbiased tyrosine kinome RNAi screen; co-immunoprecipitation; phospho-AKT/ERK western blot; apoptosis assay; dasatinib treatment in vitro and in vivo\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased screen validated by reciprocal co-IP and pharmacological dissection with defined downstream signaling readouts\",\n      \"pmids\": [\"24733895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EphB4 functions as an alternative erythropoietin (Epo) receptor that triggers downstream STAT3 signaling upon Epo binding, promoting tumor growth and progression independently of the canonical EpoR.\",\n      \"method\": \"Receptor identification experiments; STAT3 phosphorylation assay upon rhEpo stimulation; EphB4 knockdown/overexpression in cancer cell lines; in vivo tumor growth assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel receptor function identified with defined downstream pathway (STAT3), single lab\",\n      \"pmids\": [\"26481148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"EPHB4 regulates hematopoietic stem and progenitor cell (HSPC) mobilization from bone marrow through signaling interactions with ephrin B2 on hematopoietic cells; blockade of EPHB4/ephrin B2 signaling reduces HSPC mobilization and myeloid cell trafficking to tumors.\",\n      \"method\": \"Mutually exclusive localization of EPHB4 in sinusoids vs. ephrin B2 in hematopoietic cells by immunostaining; pharmacological blockade of EPHB4/ephrin B2 in mice; HSPC mobilization quantification; tumor infiltration assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment linked to functional HSPC mobilization phenotype, single lab\",\n      \"pmids\": [\"27820703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Loss-of-function mutations in EPHB4 cause capillary malformation–arteriovenous malformation type 2 (CM-AVM2); in vitro expression of multiple patient missense mutations confirmed loss of EPHB4 kinase function; RASA1 (p120RasGAP), a direct effector of EPHB4, links this to deregulation of the RAS-ERK signaling pathway.\",\n      \"method\": \"Whole-exome sequencing; in vitro expression and kinase activity assay of mutant proteins; genetic linkage; patient cohort screening\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional validation of mutations in vitro combined with genetic linkage, multiple families and mutations\",\n      \"pmids\": [\"28687708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A heterozygous EPHB4 splice-site mutation causing retention of a 12-bp intron reduces EPHB4 tyrosine phosphorylation (loss of function), leads to lymphatic vessel misbranching and developmental defects in zebrafish, and activates mTORC1 signaling; rescue with mTOR inhibitors or RAS-MAPK inhibitors restores normal vessel development.\",\n      \"method\": \"Whole exome sequencing; RNA-Seq splice analysis; transient co-expression of mutant/WT EPHB4 with phosphorylation assay; zebrafish morpholino; immunoblot for mTORC1 activity; pharmacological rescue; EPHB4 knock-in in HEK293T cells\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including in vitro kinase assay, zebrafish rescue, and cell-based knock-in confirming EPHB4→mTORC1 axis\",\n      \"pmids\": [\"29905864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Inducible, endothelial-cell-specific deletion of EphB4 in adult mice causes rupturing of cardiac capillaries, cardiomyocyte hypertrophy, and pathological cardiac remodeling; mechanistically, EphB4 controls caveolae function, cell-cell adhesion under mechanical stress, and lipid transport specifically in cardiac (but not skeletal muscle) capillaries.\",\n      \"method\": \"Inducible endothelial-specific Ephb4 knockout mice; cardiac histology and electron microscopy; caveolae functional analysis; cell-cell adhesion assay under flow; lipid transport assay; cultured endothelial cells\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inducible cell-specific KO with multiple mechanistic readouts (caveolae, adhesion, lipid transport), organ-specific phenotype characterized\",\n      \"pmids\": [\"31782728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EPHB4 inhibition in prostate cancer cells reduces GLUT3 expression, impairs glucose uptake and lowers cellular ATP, activating endoplasmic reticulum stress and immunogenic cell death (eIF2α phosphorylation, surface calreticulin, HMGB1/ATP release); this is linked to MYC downregulation via the SRC/p38 MAPK/4EBP1 signaling cascade.\",\n      \"method\": \"EPHB4 inhibition (small molecule and genetic); glucose uptake assay; ATP measurement; ER stress markers (eIF2α phosphorylation, calreticulin); HMGB1/ATP release assays; MYC western blot; SRC/p38/4EBP1 pathway analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic readouts linking EPHB4 to metabolic and ER stress pathways, single lab\",\n      \"pmids\": [\"31641103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EphrinB2/EphB4 signaling controls lymphatic endothelial cell junction stability by regulating junctional localization of the tight junction protein CLDN5 and cytoskeletal contractility via Rac1/Rho signaling; conditional gene deletion in mice showed this is dispensable for blood but required for lymphatic endothelial barrier function.\",\n      \"method\": \"Conditional gene deletion in mice (endothelial-specific); primary human lymphatic endothelial cells; immunofluorescence for CLDN5 localization; Rac1/Rho activity assays; junctional integrity functional assay\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion with mechanistic pathway (CLDN5/Rac1/Rho) validated in both mouse and human primary cells\",\n      \"pmids\": [\"32897857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Mutations in EPHB4 cause primary venous valve aplasia in humans; conditional deletion of Ephb4 in mice disrupts valve-forming endothelial cell organization, reorientation, polarity, elongation, and proliferation, and loss of ephrinB2 disrupts junctional expression of connexin37 and connexin43 around reorienting valve-forming cells.\",\n      \"method\": \"Quantitative ultrasound in patients; conditional Ephb4 and Efnb2 knockout mice; GFP reporter for expression; immunostaining for connexin37/43, cell polarity, and proliferation markers\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic mouse models with mechanistic cellular readouts correlated with human genetic disease\",\n      \"pmids\": [\"34403370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EphB4 binds directly to the insulin receptor (InsR); this interaction is markedly enhanced by insulin and facilitates clathrin-mediated InsR endocytosis and lysosomal degradation via an AP2 complex-binding motif in EphB4; hepatic EphB4 overexpression decreases InsR levels and increases insulin resistance in mice, while EphB4 inhibition improves insulin resistance in obese mice.\",\n      \"method\": \"Co-immunoprecipitation of EphB4 and InsR; AP2 motif mutation analysis; clathrin-mediated endocytosis assay; lysosomal degradation assay; hepatic overexpression and genetic/pharmacological inhibition in mice; glucose tolerance and insulin resistance tests\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding demonstrated by Co-IP, mechanism (AP2/clathrin/lysosome) confirmed by domain mutation and pathway inhibition, validated in vivo\",\n      \"pmids\": [\"36131205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EPHB4 is required for export of collagen IV from the endoplasmic reticulum in vascular endothelial cells; loss of endothelial EPHB4 causes collagen IV accumulation in the ER, leading to EC apoptosis and defective angiogenesis; this function is independent of physical interaction with RASA1 but requires EPHB4 kinase activity, and can be rescued by drugs promoting collagen IV ER export or inhibiting Ras signaling.\",\n      \"method\": \"Induced EC-specific Ephb4 knockout mice; confocal imaging of collagen IV in ER; apoptosis assays; EPHB4 mutant knock-in (RASA1 binding-deficient); pharmacological rescue with ER export promoters and Ras pathway inhibitors\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — inducible EC-specific KO, domain-specific mutant knock-in, pharmacological rescue with multiple agents, mechanistically rigorous\",\n      \"pmids\": [\"35015735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EphB4 acts as a tumor suppressor in head and neck squamous cell carcinoma: loss of EphB4 intracellular domain on cancer cells accelerates tumor growth and angiogenesis with compensatory upregulation of EphA4 and increased regulatory T cell infiltration; ephrinB2 knockout on cancer cells and vasculature produces maximal tumor reduction and vascular normalization, establishing ephrinB2 as a tumor promoter and EphB4 as a tumor suppressor in this context.\",\n      \"method\": \"Genetically engineered mice; EphB4 and ephrinB2 knockout; recombinant constructs; pharmacologic agonists and antagonists; tumor immune microenvironment analysis; EphA4 expression analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological manipulations in genetically engineered mice with defined mechanistic findings, single well-controlled study\",\n      \"pmids\": [\"35725568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"EphB4 signaling accelerates differentiation of human hematopoietic progenitor cells in a non-lineage-restricted manner, but preferentially promotes megakaryocytic and erythroid differentiation; effects are abrogated by mutations in select EphB4 tyrosine residues or by genistein (tyrosine kinase inhibitor), establishing tyrosine kinase activity and specific phosphorylation sites as required for these effects.\",\n      \"method\": \"Ectopic EphB4 expression in hematopoietic cell lines and cord blood CD34+ cells; site-directed mutagenesis of tyrosine residues; genistein inhibition; colony-forming and LTC-IC assays; differentiation marker expression\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis of tyrosine phosphorylation sites combined with functional differentiation assays, single lab\",\n      \"pmids\": [\"11929761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EphB4 in colorectal cancer liver metastases interacts with EphrinB2 via forward signaling to enhance LDLR-mediated cholesterol uptake by promoting STAT3 phosphorylation which drives LDLR transcription; blocking the EFNB2/EphB4 axis reduces LDLR expression and cholesterol uptake in liver metastasis.\",\n      \"method\": \"In vitro and in vivo metastasis models; STAT3 phosphorylation assay; LDLR expression analysis; cholesterol uptake assay; LDLR rescue experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined signaling axis (EFNB2/EPHB4→STAT3→LDLR→cholesterol) with in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"36376513\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EphB4 is a transmembrane receptor tyrosine kinase that binds ephrin-B2 on adjacent cells to initiate bidirectional (forward through EphB4 kinase and reverse through ephrin-B2) contact-dependent signaling, governing arteriovenous endothelial cell identity and sorting, vascular/lymphatic morphogenesis and integrity (via Rho/Rac, caveolae, and CLDN5 junctional mechanisms), bone homeostasis (coupling osteoblast differentiation via forward signaling to osteoclast suppression of NFATc1 via reverse signaling), and tumor cell behavior (promoting migration through RhoA-mediated actin reorganization and survival via AKT/PI3K; alternatively acting as a tumor suppressor when ligand-activated); upstream, EphB4 recruits RASA1 to suppress mTORC1 in endothelial cells, facilitates collagen IV ER export required for angiogenesis, and in hepatocytes couples insulin-stimulated AP2-clathrin-mediated endocytosis of the insulin receptor to lysosomal degradation, thereby regulating systemic insulin sensitivity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"EphB4 is a transmembrane receptor tyrosine kinase that, through bidirectional signaling with its cognate ligand ephrin-B2 on adjacent cells, governs arteriovenous endothelial identity, vascular and lymphatic morphogenesis, bone homeostasis, hematopoietic progenitor mobilization, and tumor cell behavior. Forward signaling through the EphB4 kinase domain recruits RASA1 to suppress mTORC1 in endothelial cells, activates RhoA to reorganize the actin cytoskeleton, regulates collagen IV ER export required for angiogenesis, controls caveolae function and CLDN5-dependent lymphatic junctional integrity via Rac1/Rho, and in hepatocytes couples insulin receptor internalization through an AP2-clathrin pathway to lysosomal degradation, thereby modulating systemic insulin sensitivity [PMID:24837431, PMID:16950769, PMID:35015735, PMID:32897857, PMID:31782728, PMID:36131205]. Loss-of-function mutations in EPHB4 cause capillary malformation–arteriovenous malformation type 2 (CM-AVM2) and primary venous valve aplasia in humans [PMID:28687708, PMID:34403370]. In cancer, EphB4 exhibits context-dependent dual roles: ligand-independent kinase activity promotes survival via PI3K/AKT and migration via RhoA/FAK, whereas ephrin-B2-stimulated forward signaling triggers receptor internalization/degradation and can suppress tumor growth, consistent with its tumor-suppressor function in intestinal and head-and-neck carcinogenesis [PMID:22161689, PMID:19738063, PMID:35725568].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing that EphB4 (HTK) possesses intrinsic tyrosine kinase activity and autophosphorylation capacity answered the foundational question of whether this orphan receptor signals through catalytic activity.\",\n      \"evidence\": \"In vitro kinase assay with purified protein and agonistic antibody stimulation in transfected NIH3T3 cells\",\n      \"pmids\": [\"8188704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cognate ligand not yet identified\", \"No downstream effectors known\", \"No in vivo function established\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrating that EphB4 knockout phenocopies ephrin-B2 knockout — with selective venous expression of EphB4 — established ephrin-B2 as the cognate ligand and proved that bidirectional ephrinB2/EphB4 signaling is required for angiogenesis and arteriovenous identity.\",\n      \"evidence\": \"Targeted gene knockout mice with comparative phenotypic analysis between EphB4-null and ephrin-B2-null embryos\",\n      \"pmids\": [\"10518221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Forward vs. reverse signaling contributions not individually resolved\", \"Downstream intracellular effectors unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Dissecting forward versus reverse signaling showed they have non-overlapping functions: EphB4 forward signaling inhibits endothelial adhesion while reverse signaling through ephrin-B2 does not, clarifying how bidirectionality produces asymmetric cell behaviors at arteriovenous boundaries.\",\n      \"evidence\": \"Adhesion and migration assays with sorted primary endothelial cells using immobilized Fc-fusion proteins\",\n      \"pmids\": [\"12588758\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling intermediates downstream of forward signaling not identified\", \"In vivo validation of adhesion phenotype lacking\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Multiple studies established that EphB4 kinase activity is required for migration inhibition and that kinase-dead EphB4 can still drive angiogenesis in vivo through reverse ephrin-B2 signaling, resolving that the extracellular domain alone is sufficient for reverse but not forward signaling outputs.\",\n      \"evidence\": \"Kinase-dead and truncated EphB4 constructs in cell migration assays and xenograft models; pharmacological kinase inhibition\",\n      \"pmids\": [\"15067119\", \"14672701\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific kinase substrates not identified\", \"Mechanism of reverse signaling transduction through ephrin-B2 not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"A high-resolution crystal structure of the EphB4 ligand-binding domain revealed the hydrophobic cleft for ephrin-B2 engagement, providing the first atomic-level understanding of receptor-ligand specificity and enabling rational inhibitor design.\",\n      \"evidence\": \"X-ray crystallography at 1.65 Å with ITC validation of peptide binding determinants\",\n      \"pmids\": [\"16472751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full ectodomain complex with ephrin-B2 not yet solved\", \"No structure of the kinase domain\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Three concurrent discoveries expanded EphB4's functional repertoire beyond vasculature: forward signaling through EphB4 enhances osteoblast differentiation while reverse signaling suppresses osteoclastogenesis via NFATc1; EphB4 promotes melanoma migration via RhoA-mediated actin reorganization; and EphB4 sustains breast cancer cell survival through PI3K/AKT, establishing kinase-dependent downstream effector pathways.\",\n      \"evidence\": \"Transgenic EphB4 overexpression in osteoblasts with bone histomorphometry; dominant-negative RhoA and kinase-dead constructs in melanoma cells; siRNA knockdown with caspase and AKT assays in breast cancer cells\",\n      \"pmids\": [\"16890539\", \"16950769\", \"16816380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase substrates mediating RhoA activation unknown\", \"Whether PI3K/AKT activation is direct or indirect unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Genetic lineage tracing showed that ephrinB2/EphB4 sorts arterial and venous endothelial cells into correct vessels — a function mechanistically distinct from Notch-mediated control of arterial-venous proportions — clarifying the specific developmental role of this receptor pair.\",\n      \"evidence\": \"Mouse genetic loss-of-function with endothelial cell lineage tracing, compared with Notch gain/loss-of-function\",\n      \"pmids\": [\"18952909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-autonomous sorting mechanism not molecularly defined\", \"Whether sorting requires kinase activity or reverse signaling not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that EphB4 inhibits integrin-mediated adhesion in a ligand-independent, kinase-dependent manner — reducing β1-integrin levels — revealed a constitutive signaling mode independent of ephrin-B2 engagement.\",\n      \"evidence\": \"siRNA, overexpression, and ephrin-binding-deficient point mutants with adhesion/spreading assays and β1-integrin western blots\",\n      \"pmids\": [\"19552627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of β1-integrin downregulation not elucidated\", \"Whether ligand-independent activity operates in normal physiology or only in overexpression contexts\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"EphB4 heterozygous inactivation in ApcMin mice accelerated intestinal tumorigenesis, establishing EphB4 as a haploinsufficient tumor suppressor in the intestine and showing its context-dependent oncogenic versus tumor-suppressive behavior.\",\n      \"evidence\": \"Genetic epistasis (ApcMin × EphB4+/−); tumor burden, invasion assays, xenograft models\",\n      \"pmids\": [\"19738063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tumor-suppressive mechanism downstream of EphB4 not molecularly defined\", \"Whether ligand-dependent activation is required for suppressor function unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Resolving the dual-role paradox: in the absence of ephrin-B2, overexpressed EphB4 promotes anchorage-independent growth; upon ligand stimulation, EphB4 is internalized and degraded via ERK1/2-dependent mechanisms, switching to tumor suppression — explaining how the same receptor can be oncogenic or suppressive depending on microenvironmental context.\",\n      \"evidence\": \"Ligand-stimulated vs. unstimulated EphB4 overexpression; receptor internalization, ERK1/2 phosphorylation, caspase-3/7 activity in prostate and mammary cell lines\",\n      \"pmids\": [\"22161689\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin ligase or trafficking machinery for ligand-induced degradation not identified\", \"Not validated in vivo\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of RASA1 as a direct effector recruited by EphB4 to suppress mTORC1 established the first complete signaling axis (EphB4→RASA1→mTORC1) for vascular development, and pharmacological mTORC1 inhibition rescued EphB4-deficient vascular defects, providing therapeutic proof-of-concept.\",\n      \"evidence\": \"Zebrafish genetics with engineered RASA1-binding-deficient EPHB4; mTORC1 activity assays; rapamycin rescue; patient AVM tissue phospho-S6 staining\",\n      \"pmids\": [\"24837431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RASA1 acts via Ras-GAP activity or a GAP-independent mechanism on mTORC1 not fully resolved\", \"Mammalian genetic validation of the full axis incomplete at this point\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Discovery that loss-of-function EPHB4 mutations cause CM-AVM2 in humans — with in vitro confirmation of kinase loss — established the first Mendelian disease caused by EPHB4 deficiency and linked it to the RASA1-RAS-ERK pathway.\",\n      \"evidence\": \"Whole-exome sequencing in multiple families; in vitro kinase activity assays of patient missense mutations\",\n      \"pmids\": [\"28687708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Somatic second-hit mechanism not demonstrated\", \"Genotype-phenotype correlations across mutation types not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Inducible endothelial-specific EphB4 deletion in adults revealed organ-specific (cardiac) requirements for caveolae function, cell-cell adhesion under mechanical stress, and lipid transport, expanding EphB4's role from development to adult tissue homeostasis.\",\n      \"evidence\": \"Inducible EC-specific Ephb4 knockout mice; electron microscopy of caveolae; adhesion under flow; lipid transport assays\",\n      \"pmids\": [\"31782728\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why cardiac but not skeletal muscle capillaries are affected is unexplained\", \"Direct molecular link between EphB4 and caveolae biogenesis unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"EphrinB2/EphB4 signaling was shown to maintain lymphatic endothelial barrier function by controlling CLDN5 junctional localization through Rac1/Rho, establishing a mechanistic link to lymphatic-specific (not blood vascular) integrity.\",\n      \"evidence\": \"Conditional endothelial gene deletion in mice; CLDN5 immunofluorescence; Rac1/Rho activity assays in primary human lymphatic endothelial cells\",\n      \"pmids\": [\"32897857\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How EphB4 selectively controls Rac1 vs. Rho balance in lymphatic but not blood endothelium not resolved\", \"Direct phosphorylation targets linking EphB4 to CLDN5 trafficking unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mutations in EPHB4 were shown to cause primary venous valve aplasia, with mechanistic dissection revealing that EphB4 controls valve-forming endothelial cell reorientation, polarity, and connexin37/43 junctional expression, expanding its disease spectrum beyond CM-AVM2.\",\n      \"evidence\": \"Human patient ultrasound; conditional Ephb4 and Efnb2 knockout mice; connexin37/43 immunostaining; cell polarity markers\",\n      \"pmids\": [\"34403370\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether valve aplasia results from forward signaling, reverse signaling, or both is not resolved\", \"Downstream pathway from EphB4 to connexin expression not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Four studies in 2022 greatly expanded the mechanistic scope: EphB4 directly binds the insulin receptor and promotes its AP2/clathrin-mediated endocytosis and lysosomal degradation in hepatocytes, regulating systemic insulin sensitivity; EphB4 kinase activity is required for collagen IV ER export independent of RASA1 binding; EphB4 forward signaling acts as a tumor suppressor in head-and-neck cancer; and EphB4/ephrinB2 promotes STAT3-driven LDLR transcription enhancing cholesterol uptake in liver metastases.\",\n      \"evidence\": \"Co-IP of EphB4/InsR with AP2 motif mutagenesis and in vivo glucose tolerance tests; EC-specific Ephb4 KO with RASA1-binding-deficient knock-in and pharmacological ER export rescue; genetically engineered mouse tumor models; STAT3/LDLR pathway analysis in metastasis models\",\n      \"pmids\": [\"36131205\", \"35015735\", \"35725568\", \"36376513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether EphB4-InsR interaction requires ephrin-B2 or is ligand-independent in vivo\", \"Kinase substrate mediating collagen IV ER export not identified\", \"Mechanism by which EphB4 activates STAT3 for LDLR transcription not fully dissected\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the identity of direct EphB4 kinase substrates that mediate RhoA activation, caveolae regulation, and collagen IV ER export; the structural basis for EphB4's interaction with non-canonical ligands such as Epo and the insulin receptor; and how cell-type-specific signaling outputs (cardiac vs. lymphatic vs. hepatic) are determined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct kinase substrate identified for most downstream phenotypes\", \"Full-length EphB4 kinase domain structure not solved\", \"Cell-type-specific signaling determinants remain undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 8, 14, 11]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [17, 27]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 13, 23]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 7, 8, 9, 17, 18, 25]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 10, 26]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [17, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 12, 15, 29]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [27]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [27, 31]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"EFNB2\",\n      \"RASA1\",\n      \"INSR\",\n      \"RHOA\",\n      \"PDGFRB\",\n      \"CLDN5\",\n      \"SDC1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}